What are the indications to start triptans (serotonin receptor agonists) for migraine treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Indications for Starting Triptans in Migraine Treatment

Triptans are indicated as second-line therapy for the acute treatment of moderate to severe migraine attacks when first-line over-the-counter analgesics (NSAIDs) provide inadequate headache relief. 1

Primary Indications

  • Acute treatment of migraine with or without aura in adults 2, 3
  • Second-line therapy after inadequate response to first-line medications (NSAIDs, acetaminophen) 1, 4
  • Moderate to severe migraine attacks that don't respond to initial treatment 1

Key Requirements Before Starting Triptans

  • A clear diagnosis of migraine must be established 2, 3
  • Patient should have tried and had inadequate response to first-line treatments:
    • NSAIDs (aspirin, ibuprofen, diclofenac potassium)
    • Acetaminophen (less efficacious than NSAIDs) 4

Optimal Timing and Administration

  • Triptans are most effective when taken early in an attack while headache is still mild 4
  • Should not be used during the aura phase of a migraine attack 4
  • Treatment should begin as soon as possible after migraine onset 1

Contraindications

Triptans should not be used in patients with:

  • History of coronary artery disease or coronary artery vasospasm 2
  • Wolff-Parkinson-White syndrome or other cardiac conduction disorders 2
  • History of stroke, transient ischemic attack, hemiplegic or basilar migraine 2
  • Peripheral vascular disease or ischemic bowel disease 2
  • Uncontrolled hypertension 2
  • Recent (within 24 hours) use of another triptan or ergotamine-containing medication 2
  • Concurrent or recent (past 2 weeks) use of MAO-A inhibitors 2
  • Severe hepatic impairment 2

Special Considerations

  • If one triptan is ineffective, others might still provide relief 4
  • For patients with severe nausea/vomiting, consider non-oral triptan formulations (nasal, injectable) 1
  • Sumatriptan subcutaneous injection can be useful for patients who:
    • Rapidly reach peak headache intensity
    • Cannot take oral triptans due to vomiting
    • Have failed other triptans 4

Monitoring and Precautions

  • Monitor for medication overuse headache (≥10 days/month with triptans) 1
  • Maximum dose in a 24-hour period: 200 mg for sumatriptan 2
  • A second dose should only be considered if some response to the first dose was observed 2
  • Separate doses by at least 2 hours 2

Treatment Algorithm

  1. First-line treatment: NSAIDs (aspirin, ibuprofen, diclofenac) or acetaminophen for mild attacks
  2. Second-line treatment: Add triptan if inadequate response to first-line treatment
  3. For triptan failure:
    • Try a different triptan (if one fails, others may work) 4
    • Consider combination therapy (triptan + NSAID) 1
    • For multiple triptan failures, consider third-line options like ditans (lasmiditan) or gepants (ubrogepant, rimegepant) 4

Common Pitfalls to Avoid

  • Using triptans for prophylactic therapy of migraine (not indicated) 2, 3
  • Using triptans for treatment of cluster headache without proper diagnosis 2, 3
  • Administering triptans during the aura phase 4
  • Exceeding recommended maximum daily doses 2
  • Failing to recognize medication overuse headache from frequent triptan use 1
  • Using triptans in patients with cardiovascular contraindications 2

Remember that triptans are not indicated for the prevention of migraine attacks but specifically for acute treatment when a clear diagnosis of migraine has been established 2, 3.

References

Guideline

Acute Migraine Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.